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ABSTRACT 
 
Treatment with phototherapy or with the lipase inhibitor orlistat decreases plasma 
unconjugated bilirubin (UCB) concentrations in hyperbilirubinemic Gunn rats. We 
investigated the mechanism(s) underlying the effects of orlistat, phototherapy, and combined 
treatment, using steady-state 3H-UCB kinetics. After 3 weeks of treatment with orlistat (200 
mg/kg chow), phototherapy (19 µW/cm2/nm) or combined treatment, tracer 3H-UCB was 
administered i.v. to treated and untreated (control) Gunn rats. Plasma samples and feces were 
collected every 12h for 60h, and bile for 30 min at 60h. The following results were obtained:  
a) each treatment decreased plasma bilirubin levels compared with controls: orlistat -19% 
(p<0.05), phototherapy -32% (p<0.01), combined treatment -53% (p<0.001); b) plasma 
bilirubin concentrations were strongly, negatively correlated with fractional bilirubin turnover 
(r = -0.87, p<0.001); c) orlistat treatment induced net transmucosal excretion of UCB into the 
intestinal lumen, whereas phototherapy increased biliary UCB excretion rate; d) all treatments 
profoundly increased the enterohepatic circulation of UCB derivatives, indicating enhanced 
metabolism by intestinal bacteria. In conclusion, orlistat and phototherapy lower plasma 
bilirubin concentrations in Gunn rats by increasing (net) intestinal influx of UCB, either by 
transmucosal excretion (orlistat), or increased biliary secretion (phototherapy). The 
mechanism of phototherapy and orlistat treatment involves increasing the availability of UCB 
in the intestinal lumen for fecal excretion and for metabolism by intestinal bacteria. 
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INTRODUCTION 
 
Severe unconjugated hyperbilirubinemia can cause bilirubin-induced neurologic dysfunction 
(BIND), kernicterus, and death.1 Conventional treatment for unconjugated hyperbilirubinemia 
involves phototherapy, which induces photoisomerization of unconjugated bilirubin (UCB) to 
more water-soluble derivatives that can be excreted into bile.2 Short-term phototherapy has 
relatively minor side effects and is considered safe.3  
Crigler-Najjar disease is characterized by permanent, unconjugated hyperbilirubinemia 
due to a genetic deficiency in bilirubin glucuronidation.4 Conventional treatment for Crigler-
Najjar disease (type I) involves life-long daily phototherapy. Disadvantages of long-term 
phototherapy are a declining efficacy with age and a profound impact on the quality of 
(social) life.5;6 Since the introduction of phototherapy, serious long-term effects have not been 
reported. However, there have been reports of phototherapy-induced DNA damage to human 
cell lines in vitro and bilirubin was found to enhance this damage.7;8  
An alternative treatment strategy for unconjugated hyperbilirubinemia is based on 
intestinal capture of UCB. UCB can diffuse across the intestinal mucosa from the blood into 
the intestinal lumen9;10 and vice versa.11 Capture of UCB in the intestine, by orally 
administered unabsorbable binders of UCB, can prevent its reabsorption into the 
enterohepatic circulation. Such agents, like agar, activated charcoal, and cholestyramine are 
no longer used for treatment of unconjugated hyperbilirubinemia because of inconsistent 
clinical results and side effects. Intestinal capture of UCB by calcium phosphate was very 
effective in Gunn rats,12 a well-established animal model for Crigler-Najjar disease.13 In 
Crigler-Najjar patients however, the decrease in plasma UCB concentration was less 
pronounced, and occurred only in patients treated simultaneously with phototherapy.5 
Phototherapy profoundly enhances the very limited biliary secretion of UCB that can occur in 
the absence of conjugation,14 thus increasing the amount of UCB available for capture in the 
intestine. 
Recently, we demonstrated in Gunn rats that dietary supplementation with the lipase 
inhibitor orlistat decreased plasma UCB levels, parallel to an increase in fecal fat 
excretion.15;16 Plasma UCB concentrations were strongly, negatively correlated with the 
amount of fat excreted via the feces. Orlistat treatment was equally effective as continuous 
phototherapy in Gunn rats, and combined treatment was more effective than either treatment 
alone,16 which suggests that the two treatments operate by different mechanisms. The 
mechanism by which orlistat treatment reduces plasma bilirubin levels has not been 
elucidated so far. In the present study, we used steady-state 3H-bilirubin kinetics to assess the 
mechanism(s) underlying the effects of orlistat, phototherapy, and combined treatment in 
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METHODS  
 
Animals. Homozygous male Gunn rats (RHA/jj, 220-320 g), were obtained from our breeding 
colony (University Medical Center Groningen, The Netherlands). Animals were housed in an 
environmentally controlled facility, were fed ad libitum, and were caged individually or, in 
case of phototherapy, per treatment group. The Ethics Committee for Animal Experiments 
(University of Groningen, The Netherlands) approved experimental protocols. 
Phototherapy lamps. Two phototherapy devices were developed according to the prototype 
designed by Ostrow.2 Each device consisted of two blue phototherapy lamps (Philips, TL-
20W/03T) suspended in a reflective canopy 20 cm above the bottom of the cage. 
Phototherapy (19 µW/cm2/nm; 380-480 nm; measured by an Elvos-LM-1010 Lux meter at 20 
cm distance), was administered continuously to Gunn rats, shaven on their backs and flanks. 
Chemicals. 2,3-3H-labeled 5-aminolevulinic acid (specific activity 2.0 Ci/mmol) was obtained 
from Amersham Biosciences (Piscataway, NJ). Heptadecanoic acid (C17:0) and bilirubin 
were purchased from Sigma (St Louis, MO). Orlistat was from Roche Nederland (Woerden, 
The Netherlands). 
Preparation of 3H-labeled UCB.  3H-labeled UCB (specific activity 48.8x103 dpm/µg = 12.9 
µCi/µmol) was prepared by biosynthetic labeling of bilirubin in dog bile from precursor 
labeled 2,3-3H-5-aminolevulinic acid.17 The 3H-UCB was isolated and recrystalized twice.18  
Preparation of 3H-UCB solution for i.v. administration. Under dim light, immediately 
before injection into the Gunn rats, 1.5 mg of 3H-UCB was dissolved in 1.0 ml dimethyl 
sulfoxide (DMSO). Then, 12.5 ml of Wistar rat plasma was slowly added with continuous, 
thorough mixing. 0.2 ml/100 g body weight (BW), containing 22 µg UCB/100 g BW, and 
0.49 µCi/100 g BW, was administered to each Gunn rat via the penile vein. 
Diets. Hope Farms (Woerden, The Netherlands) produced the semisynthetic, purified control 
diet (code 4063.02), that contained 13 energy% fat / 5.2 wt% long-chain fatty acids. As in 
previous studies, all Gunn rats were fed the control diet for a run-in period of 4 weeks.15;16 
The orlistat-supplemented diet was prepared by thorough mixing of orlistat (Xenical®, 200 
mg/kg chow) into the control diet. 
 
Study Design 
Pilot experiment to determine non-toxic limit of injected DMSO 
To study 3H-UCB kinetics under steady-state conditions, it was essential to prevent DMSO-
induced hemolysis, by minimizing the volume of administered DMSO, without compromising 
solubilization of bilirubin. Intravenous administration of 0.3 or 0.15 ml of DMSO (diluted 1:4 
with Wistar rat plasma) to ~300 g Gunn rats caused transient hemolysis, characterized by 
increased plasma UCB concentrations, decreased hemoglobin (Hb) and hematocrit (Ht), and 
reticulocytosis (data not shown). By contrast, when an 8 mM solution of bilirubin in DMSO 
was diluted 1:16 with Wistar rat plasma, and 0.2 ml/100g BW was administered i.v. to three 
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adult Gunn rats, samples of tail vein blood obtained 0, 6, 12, 24, 30 and 48 hours after 
injection revealed no evidence of hemolysis. Thus, in an adult male Gunn rat, i.v. 
administration of ~0.04 ml of DMSO, diluted 1:16 with rat plasma, should not alter steady-
state 3H-UCB kinetics.  
 
Effects of orlistat and/or phototherapy on steady-state bilirubin kinetics  
After 4 weeks run-in on the control diet, Gunn rats were randomly assigned to one of 4 groups 
(n = 4-6 per group), to receive either the control diet, the orlistat-supplemented diet, 
continuous phototherapy, or the combination of orlistat-supplemented diet and continuous 
phototherapy. Previously, we showed that 2 weeks of orlistat treatment is sufficient to reach 
steady-state plasma UCB concentrations and fecal UCB excretion.15 After 3 weeks of 
treatment (T0h), heparinized samples of tail vein blood were obtained under isoflurane 
anesthesia. We then administered 3H-UCB (~0.49 µCi/100 g BW) via the penile vein and 
collected blood samples every 12h for 60h to determine plasma 3H and bilirubin 
concentration. After ~60h, under pentobarbital anesthesia, bile was collected for 30 minutes 
under light-protected conditions after cannulation of the common bile duct. Bile flow was 
determined gravimetrically, assuming a density of 1 g/ml. After bile collection, blood was 
obtained by vena cava inferior puncture for determination of Hb, Ht, reticulocytes, aspartate-
aminotransferase activity (AST), and alanine-aminotransferase activity (ALT). Three days 
before T0h, feces were collected for 72h to determine steady-state fecal fat excretion. From 
T0h onwards, feces were collected every 12h for 60h to determine fecal 3H excretion. 
 
Calculation of fluxes based on steady-state 3H-UCB kinetics 
Fractional turnover of 3H-UCB (%/h) was calculated from semilogarithmic plots of 3H-UCB 
specific activity. Bilirubin pool size was calculated by dividing the calculated specific activity 
at T0h (Y-axis intercept) by the administered dose of 3H-UCB radioactivity. Total bilirubin 
turnover was calculated as the product of fractional turnover and pool size,19 and assumed to 
equal steady-state fecal excretion of UCB and derivatives. The data allowed estimation of 
steady-state fluxes of UCB and derivatives in the enterohepatic circulation during the various 
treatments. Individual fluxes were calculated as follows. Biliary excretion of UCB was 
measured by HPLC (see: Analytical Methods). With biliary excretion of UCB and specific 
activity in plasma at the time of bile collection, the percentage of 3H in bile which originated 
from 3H-UCB was calculated. Biliary excretion of derivatives was calculated by subtracting 
3H-UCB radioactivity from total biliary 3H-radioactivity measured by liquid scintillation, and 
expressed as equivalent percent of the exchangeable bilirubin pool excreted per time period. 
Net transmucosal flux of UCB was estimated by subtracting biliary UCB excretion from 
fractional UCB turnover. Total fecal excretion of UCB and its derivatives was calculated by 
dividing the total amount of dpm in feces between T12 and T60 hours, by the mean specific 
activity of UCB in plasma between T12 and T60 hours. 
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Analytical Methods   
All analytical procedures were performed in dim light. 
Plasma. Bilirubin levels were determined by reflectance spectrophotometry on a Vitros-950 
analyzer (Johnson & Johnson, Tilburg, The Netherlands), and were confirmed by HPLC 
analysis. Hb, Ht, and reticulocytes were determined on a Sysmex-XE-2100 hematology 
analyzer (Goffin Meyvis, Etten-Leur, The Netherlands). AST, and ALT were determined on a 
Mega analyzer (Merck, Darmstadt, Germany). 3H content was determined by liquid 
scintillation (Tri-Carb 2500-TR Liquid Scintillation Analyzer, Packard Bioscience, Meriden, 
CT), using two ml of Ultima Gold-XR (Packard Bioscience) scintillation fluid added to 100 
µl of plasma. Samples were counted for 10 min and quench corrected using 133Barium as 
external standard. 
Bile. For UCB measurement, bile was submitted to alkaline methanolysis and chloroform 
extraction. After evaporation under nitrogen, the residue was re-dissolved in chloroform and 
analyzed by reversed-phase HPLC, as described previously.16 3H content in 100 µl of bile was 
determined by liquid scintillation as described above.  
Feces. Feces were freeze-dried and mechanically homogenized. For determination of fatty 
acids, aliquots of feces were extracted, hydrolyzed and methylated,20 using methanol/hexane. 
Resulting fatty acid methyl esters were determined by gas chromatography (HP-Ultra-1 
column, Hewlett-Packard, Palo-Alto, CA). Fatty acid contents were calculated in molar 
amounts, using C17:0 as internal standard. For duplicate determination of 3H content, two 
aliquots (~100 mg) of feces were decolorized by incubation with 0.6 ml of NaOCl for 30 
minutes at 37ºC. Then 60 µl of NH3 was added to neutralize free chloride. After vortexing, 10 
ml of scintillation fluid was added and thoroughly mixed. After 24h, 3H content was 
determined by liquid scintillation. 
 
Statistical Analyses 
Analyses were performed using SPSS 11.0 for Windows (SPSS Inc., Chicago, IL). Results are 
expressed as mean ± SD. Based on a normal distribution of plasma bilirubin levels in large 
groups of Gunn rats,15 parametric tests were used for statistical analysis. ANOVA with post-
hoc Bonferroni correction was performed for comparisons among groups. The relationship 
between fractional 3H-UCB turnover or pool size, and plasma bilirubin concentration was 





Effects of orlistat and/or phototherapy on body weights and food intake 
Body weights at the start and end of 3 weeks of treatment were not significantly different 
among groups. All animals increased their body weight in 3 weeks (controls, 7 ± 2%; orlistat, 
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Table 1. Hematological and liver function parameters after 3 weeks of treatment
14 ± 5%; phototherapy (PT), 12 ± 8%, orlistat + PT, 7 ± 4%; not significant). As observed 
previously,15 orlistat-treated animals appeared to compensate fecal fat loss by increasing their 
food intake, compared with controls (25.6 ± 5.1 vs. 20.0 ± 2.4 g/24h, respectively; p<0.05).  
 
Effects of orlistat and/or phototherapy on plasma bilirubin concentrations 
Figure 1 shows that after 3 weeks of treatment (T0h) with orlistat or phototherapy, plasma 
bilirubin concentrations were significantly lower than in controls (-19%, p<0.05; and -32%, 
p<0.01, respectively). Efficacies of orlistat and phototherapy were not significantly different. 
Combined treatment with orlistat and phototherapy induced a more profound decrease in 
plasma bilirubin concentrations than either treatment alone (-53%, p<0.001). After i.v. 3H-
UCB administration, plasma UCB levels at 12h intervals did not change significantly 
compared with T0h values (except at T24h in the combined treatment group), in accordance 
with steady-state conditions. Also, none of the treatments significantly affected relevant 
hematological and liver function parameters (Table 1), confirming absence of significant 
hemolysis. 
 
Figure 1. Steady-state plasma bilirubin 
concentrations after i.v. administration of 3H-
UCB. Four groups of Gunn rats (n = 4-6 per 
group) were either untreated (controls ♦), or 
treated for 3 weeks with orlistat (  ), 
continuous phototherapy (PT ), or combined 
treatment (orlistat + PT ×). After 3 weeks (T0h) 
3H-UCB was injected i.v.; blood samples were 
taken at 12h intervals. Data represent mean ± 
SD. *p<0.05, **p<0.01, §p<0.001, T0h data 





















Table 1. Hematological and liver function parameters in Gunn rats after 3 weeks of either no treatment 
(controls), or treatment with orlistat, phototherapy (PT), or combined treatment (orlistat + PT). Data represent 
mean ± SD. No significant differences among groups. 
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243 ± 23*††
orlistat (n=5)




Plasma bilirubin at T0h (µmol/l)
Fractional turnover 3H-UCB (%/h)
Bilirubin pool size (µmol/100 g BW)
Total turnover bilirubin (nmol/h per 100 g BW)
143 ± 12§














951 ± 132*Fecal 3H excretion T0-60h (103 dpm) 1372‡972‡726 ± 63
Total biliary excretion of UCB + derivatives
(nmol UCB (equivalents)/h per 100 g BW)
109 ± 42155 ± 36158 ± 16109 ± 33
Total fecal excretion of UCB + derivatives 
(nmol UCB (equivalents)/h per 100 g BW)
52 ± 12 63‡59‡42 ± 9















Table 2. Steady-state 3H-bilirubin kinetics in Gunn rats after 3 weeks of either no treatment (controls), or 
treatment with orlistat, continuous phototherapy (PT), or combined treatment (orlistat + PT). After 3 weeks 
(T0h), a tracer dose of 3H-UCB (~0.5 µCi/100 g BW) was administered i.v. Plasma 3H and bilirubin levels were 
determined at 12 hour intervals for 60 hours. Feces was collected every 12 hours for 60 hours. After 60 hours 
bile was collected for 30 minutes. For calculation of fluxes see Methods section. Data represent mean ± SD. 
*p<0.05, ap=0.058 **p<0.01, §p<0.001, compared with controls. †p<0.05, ††p<0.01, bp=0.078, compared with 
orlistat + PT.  ‡SD could not be calculated due to pooled feces per group. 
 
Effects of orlistat and/or phototherapy on steady-state bilirubin kinetics 
Table 2 shows biliary UCB secretion and results of the 3H-UCB kinetics study. Similar to 
previous observations,15 orlistat treatment did not significantly affect bile flow compared with 
control Gunn rats (4.2 ± 0.9 and 3.2 ± 0.7 µl/min per 100 g BW, respectively), and neither did 
phototherapy or combined treatment (3.9 ± 0.3 and 4.0 ± 0.5 µl/min per 100 g BW, 
respectively). Biliary excretion rate of UCB tended to be higher during phototherapy (+25%), 
compared with controls, and lower during orlistat treatment (-12%) and combined treatment (-
33%), but none of these differences were statistically significant.  
Figure 2 shows a semilogarithmic plot of plasma 3H-UCB specific activities during 60h 
after 3H-UCB administration. In each of the four groups, the logarithm of plasma 3H-UCB 
specific activity declined in a linear fashion with time, in accordance with steady-state 
kinetics. Table 2 summarizes the effects of orlistat and/or phototherapy on steady-state 3H-
bilirubin kinetics. Bilirubin pool sizes, compared with controls, had decreased in each 
treatment group after 3 weeks (orlistat, -21%; PT, -23%; orlistat + PT, -42%), but statistical 
significance was only reached with combined treatment (p<0.01). Bilirubin pool sizes were 
strongly positively correlated with plasma bilirubin concentrations at T0h (r = 0.87, p<0.001, 
not shown). Total bilirubin turnover was not significantly altered by any of the treatments, 
confirming steady-state conditions and absence of (DMSO-induced) hemolysis. The quantity 
of 3H-UCB injected was <1.5% of the total UCB pool in all groups, thus representing a true 
tracer dose labeling of the UCB pool. Fractional turnover of 3H-UCB, compared with 
controls, was increased by 54% during orlistat treatment (p=0.058), by 69% during 
phototherapy (p<0.05), and by 119% during combined treatment (p<0.01).  
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Figure 2. Semilogarithmic plots of 3H-UCB specific 
activity after i.v. administration of 3H-UCB to Gunn rats. 
Experimental groups, treatments and 3H-UCB 
administration as in Figure 1. Blood samples were taken at 
12h intervals. Data represent mean values for each group. ♦ 
controls, r = -1.00;   orlistat, r = -1.00;  PT, r = -0.99; × 









Figure 3 shows that fractional turnover of 3H-UCB and plasma bilirubin concentrations at T0h 
were negatively, linearly correlated (r = -0.87, p<0.001), indicating that the differences in 
plasma bilirubin concentration between controls and treated groups were related to 
stimulation of fractional turnover of bilirubin in the treated animals. 
 
 
Figure 3. Negative linear relationship between fractional 
turnover of 3H-UCB and steady-state plasma bilirubin levels at 
T0h in Gunn rats. Experimental groups, treatments and 3H-
UCB administration as in Figure 1. Each symbol represents 
data obtained in an individual animal. r = -0.87, p<0.001. ♦ 









Effects of orlistat on fecal fat and 3H excretion  
In agreement with our previous data,15;16 orlistat treatment increased fecal fat excretion.  Fatty 
acid concentration in feces collected for 72h was significantly higher in orlistat-treated 
animals (0.44 ± 0.08 mmol/g freeze-dried feces; p<0.001), compared with controls (0.04 ± 
0.01). Orlistat treatment also increased dry fecal weight (3.7 ± 0.7 g/24h) compared with 
controls (2.5 ± 0.3; p<0.01), and cumulative fecal 3H excretion between T0h and T60h (+31%, 
p<0.05, Table 2). Fecal fat excretion per individual animal could not be calculated for the 
phototherapy or combined treatment group because these animals were housed together per 
treatment group. In pooled fecal samples from these rats, fatty acid concentrations were 
respectively 0.32 mmol/g feces (combined treatment) and 0.05 mmol/g feces (phototherapy). 
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Cumulative 3H excretion in the pooled fecal samples of the phototherapy group was 
comparable to the orlistat group. With combined treatment, cumulative 3H excretion was 




We investigated in Gunn rats the mechanism(s) underlying the hypobilirubinemic effects of 
orlistat, phototherapy and combined treatment, using steady-state 3H-UCB kinetics. Our data 
indicate that orlistat treatment and phototherapy lower plasma bilirubin concentrations in 
Gunn rats by increasing intestinal influx of UCB, either by transmucosal excretion (orlistat), 
or increased biliary secretion (phototherapy). By increasing intestinal influx of UCB, it 
becomes available for fecal elimination and/or for metabolism by intestinal bacteria, both of 
which interrupt the enterohepatic circulation of UCB. 
In the assessment of bilirubin turnover rates, it is crucial to work at steady-state 
conditions. We therefore performed a pilot experiment to define the threshold of i.v. DMSO 
administration to avoid hemolysis. Steady-state conditions in the 3H-UCB kinetics study were 
confirmed by the following observations: 1) in each group, plasma bilirubin concentrations 
remained stable during the study (Fig. 1). Previously, we showed that plasma UCB 
concentrations in Gunn rats did not change significantly between 2 and 24 weeks of orlistat 
treatment;15 2) total bilirubin turnover was unaltered compared with controls (Table 2). Under 
steady-state conditions, total bilirubin turnover equals UCB production rate. Neither 
phototherapy nor orlistat treatment has been shown to affect UCB production rate;21 3) 
relevant hematological parameters were stable (Table 1); and, finally, 4) 3H-UCB specific 
activities declined in a semilogarithmic fashion in each of the four groups (Fig. 2).  
Not all individual parameters of bilirubin kinetics were significantly different between 
the various treatments and controls (Table 2). Yet, plasma bilirubin levels were strongly, 
negatively correlated with fractional turnover of 3H-UCB (Fig. 3). This observation indicates 
that phototherapy and orlistat treatment both decrease plasma UCB concentrations via 
stimulation of bilirubin turnover. The present study also showed a strong, positive correlation 
between plasma UCB concentrations and bilirubin pool size, indicating that plasma UCB 
concentrations closely reflected UCB pool sizes during these (steady-state) treatments. The 
decrease in UCB pool size during phototherapy (-23%) is almost identical to results reported 
by Cohen et al. (-22%).21 Pool sizes were essentially the same in orlistat versus phototherapy 
treated Gunn rats and efficacies of orlistat and phototherapy were not significantly different, 
as shown previously.16 However, in the current study, orlistat seemed to be slightly less 
effective than phototherapy in decreasing plasma UCB concentrations. This suggests that 
there was a different distribution of the UCB pool between plasma and tissues in orlistat 
versus phototherapy-treated Gunn rats.  
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The present study allowed estimation of steady-state fluxes of UCB and its derivatives in the 
enterohepatic circulation under the four experimental conditions (Figure 4). Calculations are 
based on the assumption that quantitative disposal of bilirubin and its derivatives from the 
body occurs exclusively via the feces; i.e., fecal excretion of UCB plus derivatives equals 

































Figure 4. Fractional steady-state biliary and fecal fluxes of UCB and derivatives, and calculated net 
transmucosal flux of UCB in Gunn rats after 3 weeks of either no treatment (controls), or treatment with orlistat, 
continuous phototherapy (PT), or combined treatment (orlistat + PT). Fluxes of UCB and derivatives were 
determined from tracer 3H-UCB kinetic data, as described in Methods. UCB fluxes are expressed as % of the 
exchangeable (plasma + tissue) bilirubin pool excreted per hour. Derivatives fluxes are expressed as equivalent% 
of the exchangeable bilirubin pool excreted per hour. [a] = fractional turnover of UCB; [b] = fractional biliary 
excretion of UCB; [c] = fractional biliary excretion of derivatives; [d] = fractional fecal excretion of UCB + 
derivatives (equals [a] in a steady-state, under the assumption that turnover of plasma UCB is completely 
determined by fecal excretion of UCB and derivatives); [e] = estimated net transmucosal flux of UCB, from 
intestinal lumen to blood or vice versa, calculated as [a]-[b]. EHC = enterohepatic circulation. Ovals in upper left 
of each panel show bilirubin pool size (µmol/100 g BW; mean ± SD).  
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This assumption seems reasonable, since, in Gunn rats, urinary secretion of labeled UCB and 
its derivatives (consisting of polar photoderivatives, urobilinoids and other bacterial 
metabolites) is limited (~5%).10;22 Our calculations are also based on the assumption that 
metabolism of UCB to UCB-derivatives quantitatively occurs only in the intestinal lumen. It 
does, therefore, not take into account oxidative catabolism of UCB that could occur, e.g., in 
the liver. This catabolism is, however, relatively small in the untreated Gunn rat.21;23 Net 
transmucosal flux of UCB from the intestinal lumen into the blood or vice versa was 
calculated by subtracting biliary UCB excretion from fractional UCB turnover. It needs to be 
emphasized that the estimate reflects the net difference between the unidirectional fluxes of 
UCB from and into the intestinal lumen, whereas individual fluxes may be substantially 
different between treatments.  
The main results obtained from the calculations are: a) phototherapy increases biliary 
excretion of UCB and its derivatives; b) orlistat treatment induces net transmucosal excretion 
of UCB into the intestinal lumen; c) treatment with phototherapy and/or orlistat enhances 
catabolism of UCB to derivatives that undergo efficient enterohepatic circulation; d) 
combined treatment with orlistat and phototherapy more effectively increases the amount of 
UCB in the intestinal lumen and its subsequent disposal than either treatment alone. The main 
results will now be discussed consecutively in more detail.  
The experimental design and mathematical modeling of the present study allowed 
assessment of the turnover and metabolism of labeled derivatives as well as 3H-UCB. 
Phototherapy enhanced biliary excretion of UCB, as shown previously.2 A novel finding of 
the present study is that phototherapy also enhances biliary excretion of UCB derivatives. The 
increased biliary excretion of derivatives in the phototherapy group is most likely the 
consequence of enterohepatic recirculation of urobilinogens and other metabolites due to 
enhanced supply of substrate in the intestinal lumen. Previously, Schmid et al.10 and Kotal et 
al.9;24 showed that labeled UCB derivatives in Gunn rat bile are mostly urobilinogen and other 
diazo-negative polar products. Interestingly, the fractional flux of derivatives undergoing 
enterohepatic circulation is increased during phototherapy, compared with controls. This 
suggests that enhanced conversion (metabolism) of UCB to derivatives in the intestine 
quantitatively contributes to the hypobilirubinemic effect of phototherapy in Gunn rats. 
Another novel finding of the present study is the highly efficient reabsorption and 
enterohepatic circulation of UCB-derivatives in all four groups. Our data do not permit 
calculation of derivative pool sizes, nor the exact percentages of derivatives that were 
reabsorbed into the enterohepatic circulation.  
Detailed analysis of (radiolabeled) photoisomers was not performed. It has been shown 
previously that the contribution of photoisomers to plasma radioactivity, originating from 
tracer radiolabeled UCB administered i.v. to Gunn rats, is minor.2 This is probably due to 
much more rapid hepatic clearance and biliary excretion of photoisomers by the Gunn rat.25 
That study also documented that the major photoisomer in bile was cyclized, stable 
                                                                                                         
3H-UCB kinetics in treated Gunn rats 
  
  97 
photobilirubin II, whereas unstable photobilirubins IA&B rapidly reverted to UCB. There is 
no reason to believe that results in our Gunn rats would be different. 
Our estimation of fluxes assumes that almost all 3H in blood is UCB. Others have shown 
previously with 14C labeled UCB that only a very small amount of label is present in plasma 
urobilinogen. Our steady-state turnover rates are comparable with those found with 14C 
labeled UCB.2;10 The exchange rate of 14C with other C atoms is much lower than that of 3H 
with H-atoms, e.g. H2O. Furthermore, the fact that we measure more radioactivity in bile 
relative to plasma turnover indicates that UCB derivatives apparently undergo rapid 
enterohepatic circulation, but do not enter the systemic circulation, presumably due to a rapid 
first-pass effect in the liver. Finally, 3H-label exchange with water is not likely considering 
the following. We utilized 3H-UCB prepared biosynthetically in dogs by administration of 
2,3-3H-5-aminolevulinic acid17 based on the method of Howe et al.26. As stated by them, all 
tritium atoms in the labeled UCB are in stable positions on the side chains. They documented 
this directly by showing that, after simultaneous i.v. administration of 3H-UCB and 14C-UCB 
to humans, plasma disappearance curves of 3H and 14C radioactivity were superimposable for 
periods ranging from 12 hours to 16 days. Comparable results were obtained by Lester and 
Klein27 with the supposedly less stable 3H-UCB prepared from 3,5-3H-5-aminolevulinic in 
rats; the 3H/14C-ratio of the two labeled UCB excreted in rat bile was constant over a period of 
24 hours.  
Orlistat reduces absorption of dietary fats through inhibition of gastrointestinal lipases.28 
Based on a strong negative correlation between the amount of fat excreted via the feces and 
plasma UCB concentrations in Gunn rats, we hypothesized that orlistat treatment diminishes 
the enterohepatic circulation of UCB via intestinal capture of UCB by unabsorbed fat.15;16 In 
the two groups treated with orlistat (± phototherapy), there was indeed net transmucosal 
passage of UCB from the blood into the intestinal lumen, and enhanced fecal excretion of 
UCB and its derivatives, compatible with the proposed concept. In addition, however, the 
hypobilirubinemic effect of orlistat appears to result from increased metabolism of UCB to 
derivatives. As with phototherapy, the increased intraluminal pool of UCB during orlistat 
treatment appears to provide increased substrate for intestinal metabolism. Vitek et al.29 
recently showed that plasma UCB concentration increases significantly in Gunn rats in which 
conversion of UCB to urobilinoids by anaerobic intestinal flora was prevented by treatment 
with antibiotics. We cannot exclude the possibility that phototherapy or orlistat alters the 
composition of the intestinal microflora and/or their capacity to metabolize UCB, in addition 
to increasing the amount of UCB available in the intestinal lumen for microbial metabolism. 
In the combined treatment group, the increased influx of UCB into the intestine appeared 
to be due mainly to enhanced net transmucosal UCB excretion, since biliary UCB secretion 
was lower in the combined treatment group than in the phototherapy group. This may be 
related to the greater decrease in steady-state plasma UCB concentration in the combined 
treatment group, since phototherapy is less effective at lower plasma UCB concentrations due 
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to depletion of the bilirubin pool in the skin, which is the main target of phototherapy.21;30 In 
addition, one could speculate that orlistat treatment induces net transmucosal transport of 
photoisomers of UCB, although these compounds are considered relatively water-soluble. 
In conclusion, orlistat treatment and phototherapy lower plasma bilirubin concentrations 
in Gunn rats by increasing intestinal influx of UCB, either by transmucosal excretion 
(orlistat), or increased biliary secretion (phototherapy). Combined treatment has an additive 
effect. The mechanism of phototherapy and of orlistat treatment involves increasing the 
availability of UCB in the intestinal lumen for subsequent fecal excretion and for metabolism 
by intestinal bacteria. We speculate that manipulation of the metabolizing capacity of the 
intestinal flora (antibiotics, probiotics) will influence the hypobilirubinemic effects of 
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